These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38622970)

  • 1. Alpha lipoic acid administration improved both peripheral sensitivity to insulin and liver clearance of insulin reducing potential risk of diabetes and nonalcoholic fatty liver disease in overweight/obese PCOS patients.
    Genazzani AD; Battipaglia C; Rusce L; Prampolini G; Aio C; Ricciardiello F; Foschi M; Sponzilli A; Semprini E; Petrillo T
    Gynecol Endocrinol; 2024 Dec; 40(1):2341701. PubMed ID: 38622970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial diabetes predisposes PCOS patients to insulin resistance (IR), reproductive impairment and hepatic dysfunction: effects of d-chiro inositol (DCI) and alpha lipoic acid (ALA) administration on hepatic insulin extraction (HIE) index.
    Genazzani AD; Battipaglia C; Petrillo T; Piacquadio N; Ambrosetti F; Arnesano M; Semprini E; Sponzilli A; Tomatis V; Simoncini T
    Gynecol Endocrinol; 2022 Aug; 38(8):681-688. PubMed ID: 35748584
    [No Abstract]   [Full Text] [Related]  

  • 3. Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both.
    Genazzani AD; Prati A; Marchini F; Petrillo T; Napolitano A; Simoncini T
    Gynecol Endocrinol; 2019 Dec; 35(12):1088-1093. PubMed ID: 31304823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients.
    Genazzani AD; Shefer K; Della Casa D; Prati A; Napolitano A; Manzo A; Despini G; Simoncini T
    J Endocrinol Invest; 2018 May; 41(5):583-590. PubMed ID: 29090431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of nonalcoholic fatty liver disease increased with type 2 diabetes mellitus in overweight/obese youth with polycystic ovary syndrome.
    Patel-Sanchez N; Perito E; Tsai P; Raymond-Flesch M; Lodish M; Sarkar M
    J Pediatr Endocrinol Metab; 2023 May; 36(5):441-446. PubMed ID: 37060356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of d-chiro-inositol and alpha-lipoic acid combination on COH outcomes in overweight/obese PCOS women.
    Artini PG; Obino MER; Micelli E; Malacarne E; Vacca C; Papini F; Cela V
    Gynecol Endocrinol; 2020 Sep; 36(9):755-759. PubMed ID: 32157927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome.
    Macut D; Bjekić-Macut J; Livadas S; Stanojlović O; Hrnčić D; Rašić-Marković A; Milutinović DV; Mladenović V; Andrić Z
    Curr Pharm Des; 2018; 24(38):4593-4597. PubMed ID: 30652641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome.
    Macut D; Tziomalos K; Božić-Antić I; Bjekić-Macut J; Katsikis I; Papadakis E; Andrić Z; Panidis D
    Hum Reprod; 2016 Jun; 31(6):1347-53. PubMed ID: 27076501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic manifestations of women with polycystic ovary syndrome.
    Chen MJ; Ho HN
    Best Pract Res Clin Obstet Gynaecol; 2016 Nov; 37():119-128. PubMed ID: 27107966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors.
    Tfayli H; Ulnach JW; Lee S; Sutton-Tyrrell K; Arslanian S
    J Clin Endocrinol Metab; 2011 May; 96(5):1311-9. PubMed ID: 21325466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS].
    Cappelli V; Di Sabatino A; Musacchio MC; De Leo V
    Minerva Ginecol; 2013 Aug; 65(4):425-33. PubMed ID: 24051942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome.
    Li M; Yang M; Zhou X; Fang X; Hu W; Zhu W; Wang C; Liu D; Li S; Liu H; Yang G; Li L
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1485-93. PubMed ID: 25675380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome.
    Wang D; Nan N; Bing H; He B
    Front Endocrinol (Lausanne); 2023; 14():1241734. PubMed ID: 37720537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha Lipoic Acid Efficacy in PCOS Treatment: What Is the Truth?
    Guarano A; Capozzi A; Cristodoro M; Di Simone N; Lello S
    Nutrients; 2023 Jul; 15(14):. PubMed ID: 37513627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome.
    Asfari MM; Sarmini MT; Baidoun F; Al-Khadra Y; Ezzaizi Y; Dasarathy S; McCullough A
    BMJ Open Gastroenterol; 2020 Aug; 7(1):. PubMed ID: 32784205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease.
    Macut D; Božić-Antić I; Bjekić-Macut J; Tziomalos K
    Eur J Endocrinol; 2017 Sep; 177(3):R145-R158. PubMed ID: 28694246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of socio-demographic and clinical characteristics of PCOS patients attending a tertiary care institute in Colombo.
    Ranathunga I; Athukorala TG; Sumanatilleke MR; Somasundaram NP
    BMC Endocr Disord; 2022 Nov; 22(1):289. PubMed ID: 36411444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial.
    Zhang J; Xing C; Cheng X; He B
    Front Endocrinol (Lausanne); 2022; 13():1003238. PubMed ID: 36147577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical prediction score of nonalcoholic fatty liver disease in adolescent girls with polycystic ovary syndrome (PCOS-HS index).
    Carreau AM; Pyle L; Garcia-Reyes Y; Rahat H; Vigers T; Jensen T; Scherzinger A; Nadeau KJ; Cree-Green M
    Clin Endocrinol (Oxf); 2019 Oct; 91(4):544-552. PubMed ID: 31301251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients.
    Genazzani AD; Santagni S; Rattighieri E; Chierchia E; Despini G; Marini G; Prati A; Simoncini T
    Gynecol Endocrinol; 2014 Jun; 30(6):438-43. PubMed ID: 24601829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.